Kunwar Shailubhai
Principal investigator, leads SYNERGY PHARMACEUTICALS, INC..
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2024First federal award
$757KFederal grants as PI3 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
3 awards · $757K
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 3, 2025 | NIH | SBIR Phase I Combination of formulated dolcanatide, a guanylate cyclase-C agonist, with formulated atiprimod, a JAK-STAT inhibitor, for treatment of murine colitis. | $358K | NOUS BIOSCIENCES INC |
| Jun 17, 2025 | NIH | SBIR Phase I Microsphere-based formulation of dolcanatide to prevent colon carcinogenesis | $91K | NOUS BIOSCIENCES INC |
| Jun 12, 2024 | NIH | SBIR Phase I Microsphere-based formulation of dolcanatide to prevent colon carcinogenesis | $309K | NOUS BIOSCIENCES INC |
Peer ranks
Federal funding#2,011
Awards as PI#822
Patents#273
Companies
- SYNERGY PHARMACEUTICALS, INC.Leads (SEC Form D) · Software
- NOUS BIOSCIENCES INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.